Compare BioNTech SE - ADR (BNTX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Valero Energy Corporation — how do they compare? BioNTech SE - ADR trades at $93.16 (market cap $23.31B), while Valero Energy Corporation trades at $328.8 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 4× BioNTech SE - ADR's market cap, and Valero Energy Corporation pays a 1.48% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | VLO | |
|---|---|---|
Market Cap | $23.31B | $93.27B |
Sector | Health | Energy |
52-Week High | $119.34 | $323.92 |
52-Week Low | $83.89 | $133.38 |
Enterprise Value | $6.60B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Valero Energy (VLO) trades at $328.43, up 4.28% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with key resistance at $329 and support at $319. Recent Q2 2026 results significantly exceeded expectations with EPS of $12.54 versus $10.11 estimates, driven by robust refining margins and renewable diesel performance. Revenue trends show recovery from 2025's $122.7B to projected $139.4B in 2026.
VLO presents a compelling value opportunity with attractive valuation metrics (P/E 13.51, P/S 0.7) and strong profitability (ROE 29.31%). Analyst consensus favors Buy ratings (55.55%) with $324.27 price target. Key risks include refining margin volatility and geopolitical impacts on oil markets. The company's disciplined capital allocation and dividend payments ($1.20 quarterly) provide shareholder returns amid energy sector transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
